Bristol-myers Squibb Compnay

Stephen P O'Connor

Yan Shi

Philip D Stein

Chi Li

Jeffrey A Robl

Lawrence G Hamann

Zhenqiu Hong

Michael R Lawrence

William R Ewing

Jun Li

Dean A Wacker

Gregory S Bisacchi

James J Li

Bruce A Ellsworth

Jun Shi

Lawrence J Kennedy

Andres S Hernandez

Zhengxiang Gu

Haixia Wang

Elizabeth Anne Jurica

Ximao Wu

The present invention provides compounds of Formula (I): (Formula (I), or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR40 G protein-coupled receptor modulators which may be used as medicaments. 

Dihydropyrazole GPR40 modulators

Novel compounds are provided which are 1 1-beta-hydroxysteroid dehydrogenase type I inhibitors. 1 1-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 1 1-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure: W-L-Z or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein W, L are defined herein and Z is selected from the following bicyclic heteroaryl groups: (a), (b), (c), (d). 

Substituted [1,2,4]triazolo[4,3-A]pyrazine 11-beta-hydroxysteroid dehydrogenase inhibitors

Novel compounds of structure Formula I: or an enantiomer, a diastereomer, or a pharmaceutically acceptable salt thereof, wherein n, R, R, Rand Rare defined herein, are provided which are GPR119 G protein-coupled receptor modulators. GPR119 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring GPR119 G protein-coupled receptor modulator therapy. Thus, the disclosure also concerns compositions comprising these novel compounds and methods of treating diseases or conditions related to the activity of the GPR119 G protein-coupled receptor by using any of these novel compounds or a composition comprising any of such novel compounds.

Pyrimidinylpiperidinyloxypyridinone analogues as GPR119 modulators

Compounds are provided having the formula: wherein R, R, R, R, R, R, R, R, X, Y and Z are as defined herein.

Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase IV and methods

Compounds are provided having the following structure and pharmaceutically acceptable salts thereof, wherein R, R, R, R, U, V, W, Y, and n are as defined above, A method for treating the above diseases employing the above compounds is also provided.

HMG-CoA reductase inhibitors and method

Sulfonamide lactams of the following formula wherein X, R, R, R, R, R, R, R, R, R, Rand Rare as described herein, are provided which inhibitors of Factor Xa and are useful as anticoagulants in the treatment of cardiovascular diseases associated with thromboses.

Sulfonamide lactam inhibitors of FXa and method

Lactam inhibitors of factor Xa and method

Lactam inhibitors of FXa and method

Caprolactam inhibitors are provided which have the structure

Growing community of inventors

Newtown, PA, United States of America

Stephen P O'Connor